Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug2204 | Low-Carbohydrate Diet Wiki | 0.71 |
| drug2143 | Linagliptin tablet Wiki | 0.71 |
| drug1955 | Insulin Wiki | 0.71 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| D006943 | Hyperglycemia NIH | 1.00 |
| D004700 | Endocrine System Diseases NIH | 0.50 |
| D018149 | Glucose Intolerance NIH | 0.41 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| HP:0000818 | Abnormality of the endocrine system HPO | 0.50 |
| HP:0000819 | Diabetes mellitus HPO | 0.12 |
Navigate: Correlations HPO
There are 2 clinical trials
The proposed randomized controlled trial will test the effect of a low-carbohydrate diet on hemoglobin A1c among individuals with elevated hemoglobin A1c that are within the range of prediabetes or diabetes. Results may provide evidence about the role of carbohydrate restriction in individuals with or at high risk of type 2 diabetes.
Description: Based on 10-year cardiovascular disease risk assessed by 2013 American College of Cardiology/American Heart Association Atherosclerotic Cardiovascular Disease Risk Score
Measure: Change in estimated cardiovascular disease risk Time: Baseline and six monthsSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection has been a world health issue during the last months, affecting mostly countries with a high metabolic risk, like Mexico. Patients with type 2 diabetes (T2D) have an increased risk of any kind of infection as well as an increased mortality risk. Hyperglycemia has been established as an important predictor of mortality in patients with T2D and SARS-CoV-2. The standard treatment of hyperglycemia in hospitalized patients has been basen on insulin schemes, but recently evidence suggest the utility of some other drugs, reducing the risk of hypoglucemia and increasing the probability of a proper metabolic control. The goal of this study is to compare the utility of dipeptidyl peptidase-4 inhibitor (DPP4i) as a combination with insulin on metabolic control and prognosis in hospitalized patients with SARS-CoV-2 and hyperglycemia.
Description: Glucose levels during hospitalization
Measure: Glucose levels Time: 5-10 daysDescription: Patients who achieve fasting glucose levels below 140 mg/dl and posprandial levels below 180 mg/dl
Measure: Number of patients who achieve metabolic control Time: 5-10 daysDescription: If the patient requires mechanical ventilation or dies
Measure: Number of patients who die or need mechanical ventilation Time: 5-10 daysDescription: C reactive protein measured at basal and at 5-10 days in mg/dl
Measure: C reactive protein levels Time: 5-10 daysAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports